Form 4: CEO Michael Handley Exercises Valion Bio Stock Options
Statement of Changes in Beneficial Ownership
Valion Bio CEO Michael Handley acquired 2,206 shares of common stock through the vesting of restricted stock units.
Summary
- CEO Michael Handley exercised 2,206 restricted stock units (RSUs) on May 18, 2026.
- Each RSU converted into one share of common stock at no additional cost.
- Following the transaction, the CEO holds a total of 11,030 shares of common stock directly.
- The remaining unvested balance of the original RSU grant is 24,265 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and does not indicate a change in company strategy or financial health.
Positives
- The CEO continues to increase his direct equity stake in the company through the vesting of performance-based or time-based compensation.
Negatives
- None identified.
Risks
- Future vesting of the remaining 24,265 RSUs is subject to continued employment and the terms of the original grant agreement.
Future Outlook
The remaining 24,265 restricted stock units are scheduled to vest in twelve successive equal quarterly installments, completing full vesting on the fourth anniversary of the vesting commencement date.
Industry Context
StockSavvy.ai notes that executive equity vesting is a standard component of compensation packages in the biotechnology sector, intended to align management interests with long-term shareholder value.
Comparison to Industry Standards
- The vesting schedule described is consistent with standard four-year equity incentive plans common among mid-cap and growth-stage biotech firms.
- The use of RSUs as a primary retention tool is standard practice for executive compensation in the industry.
Stakeholder Impact
- Shareholders may view the CEO's increased equity stake as a positive sign of alignment with long-term company performance.
Next Steps
- Continued quarterly vesting of the remaining 24,265 restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 05/18/2026 | Date of the RSU vesting and acquisition of common stock. |
| 05/20/2026 | Date the Form 4 was signed and filed. |
Keywords
Valion Bio, VBIO, Insider Trading, Form 4, Executive Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.